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Dual Inhibition of Bcl-2/Bcl-xL 
and XPO1 is synthetically lethal in 
glioblastoma model systems
Enyuan Shang4, Yiru Zhang1, Chang Shu1, Chiaki Tsuge Ishida1, Elena Bianchetti1, Mike-
Andrew Westhoff2, Georg Karpel-Massler3 & Markus D. Siegelin1
XPO1 has recently emerged as a viable treatment target for solid malignancies, including glioblastoma 
(GBM), the most common primary malignant brain tumor in adults. However, given that tumors 
become commonly resistant to single treatments, the identification of combination therapies is critical. 
Therefore, we tested the hypothesis that inhibition of anti-apoptotic Bcl-2 family members and XPO1 
are synthetically lethal. To this purpose, two clinically validated drug compounds, the BH3-mimetic, 
ABT263, and the XPO1 inhibitor, Selinexor, were used in preclinical GBM model systems. Our results 
show that inhibition of XPO1 reduces cellular viability in glioblastoma cell cultures. Moreover, addition 
of ABT263 significantly enhances the efficacy of XPO1 inhibition on the reduction of cellular viability, 
which occurs in a synergistic manner. While selinexor inhibits the proliferation of glioblastoma cells, the 
combination treatment of ABT263 and selinexor results in substantial induction of cell death, which 
is accompanied by activation of effector- initiator caspases and cleavage of PARP. Mechanistically we 
find that XPO1 inhibition results in down-regulation of anti-apoptotic Mcl-1 and attenuates ABT263 
driven Mcl-1 up-regulation. Consistently, siRNA mediated silencing of Mcl-1 sensitizes for ABT263 
mediated cell death and partially for the combination treatment. By using a human patient-derived 
xenograft model of glioblastoma in mice, we demonstrate that the combination treatment of ABT263 
and Selinexor reduces tumor growth significantly more than each compound alone. Collectively, these 
results suggest that inhibition of XPO1 and Bcl-2/Bcl-xL might be a potential strategy for the treatment 
of malignant glial tumors.
The purpose of this study is the characterization of a novel treatment strategy for glioblastoma, a primary glial 
brain tumor that despite significant scientific progress still has a bad prognosis. In this context, XPO11,2 has been 
suggested as a target for glioblastoma since recently it was shown that the compound selinexor is capable of cross-
ing the blood brain barrier and extends survival in patient-derived orthotopic glioblastoma xenograft models3. 
Moreover, XPO1 inhibition was effective against stem-like GBM cells3, a fraction of cells that is known to drive 
resistance for therapy and recurrence. The in vitro efficacy of selinexor (IC50 – values) were reported to be in the 
low nano-molar range, reinforcing the potential treatment applicability of this drug.
The anti-apoptotic Bcl-2 family members are viable targets for glioblastoma given the fact that they are 
up-regulated in these tumors4. This is also supported by many preclinical studies that show that Bcl-2 family 
members are implicated in apoptosis regulation in model systems of these tumors. Over the last decade, several 
inhibitors were designed that inhibit the anti-apoptotic Bcl-2 family members5–8, especially Bcl-2, Bcl-xL and 
more recently Mcl-1, such as ABT199 and ABT2639. Since ABT199 has reached clinical testing and received early 
FDA-approval in hematological malignancies10–12, it is considered to be the most promising molecule out of this 
family. The appeal of ABT199 lies in the fact that it inhibits Bcl-2 with high-affinity, while having significantly less 
binding to Bcl-xL. However, the major disadvantage is that solid tumors often rely either on Bcl-xL or a combina-
tion of both Bcl-2 and Bcl-xL for their survival. Therefore, the former compound ABT263 remains still a desirable 
drug candidate since it dually inhibits Bcl-xL and Bcl-2 and it has reached clinical testing as well. To complicate 
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matters further, Mcl-1 is often increased in the context of Bcl-xL/Bcl-2 inhibition, necessitating to search for 
strategies to counteract this compensatory increase. Earlier work has suggested that XPO1 inhibition suppresses 
Mcl-1 levels3 and therefore may be a prime candidate for sensitization to Bcl-xL inhibition mediated cell death.
In this work, we have found that XPO1 inhibition down-regulates Mcl-1 protein levels and diminished 
ABT263 driven Mcl-1 increase. In turn, we demonstrate that the combination treatment of ABT263 and Selinexor 
reduces cellular viability and tumor growth synergistically in vitro and in a patient-derived xenograft model of 
glioblastoma.
Results
High levels of XPO1 expression in the TCGA database confer a bad prognosis in low-grade gliomas. 
Although XPO1 has been established as a potential drug target for malignant glial brain tumors, we still inter-
rogated the TCGA data base for low grade gliomas to assess as to whether or not XPO1 mRNA levels have a 
prognostic impact on patients with low grade gliomas. We found that high levels of XPO1 predict a worse clinical 
outcome with respect to survival (Supplementary Figure 1B). These findings support the notion that targeting 
XPO1 might be beneficial for the treatment of glial brain tumors.
XPO1 inhibition results in synergistic reduction of glioblastoma cell growth by induction of cell 
death with features of apoptosis. Our findings indicate that increasing concentrations of selinexor reduce 
the proliferation of glioblastoma cell cultures (GBM12 (patient-derived xenograft cells, LN229 and T98G), which 
was most efficient in LN229 GBM cells (Fig. 1A). Since single treatment approaches are prone to fall short of 
expectations with regards to durability of their anti-cancer effects, we tested XPO1 inhibition in the context of a 
novel combination therapy, involving BH3-mimetics. Given the efficacy of Bcl-xL inhibition in solid malignancies, 
we initiated our studies with ABT263. Unequivocally, we found that ABT263 potently reduced the IC50 values of 
selinexor in all GBM cells tested (Fig. 1A), suggesting that selinexor and ABT263 act synergistically to reduce pro-
liferation. Similar results were also obtained in stem-like GBM cells, NCH644 (Supplementary Figure 1C). In order 
to formally evaluate synergism, we tested the combination therapy of ABT263 and Selinexor over a broad range of 
concentrations. We found that based on an synergism analysis selinexor and ABT263 synergistically reduced the 
proliferation of LN229, T98G, GBM12 and U87 GBM cells (Fig. 1B,C and Supplementary Figure 1D).
Next, we determined the functional implications of anti-apoptotic Bcl-2 family members on the 
anti-proliferative effect of the combination therapy. To this end, we took advantage of the recently developed 
selective BH3-mimetics, ABT199 (Bcl-2), WEHI-539 (Bcl-xL) and A1210477 (Mcl-1). While all selective 
BH3-mimetics enhanced the reduction of cellular proliferation mediated by selinexor, the most efficacious com-
pound was the Bcl-xL inhibitor, WEHI-539 (Fig. 1D and Supplementary Figure 1A).
Based on the notion that essentially almost all combination therapies, involving BH3-mimetics, work through 
enhancement of intrinsic apoptosis, we determined activation of apoptosis induced by the combination treat-
ment of selinexor and ABT263, utilizing several state-of-the art methods. First, we treated our three GBM cell 
lines with ABT263, selinexor and the combination treatment of ABT263+ Selinexor and subsequently performed 
DNA-staining, followed by flow-cytometric analysis. These experiments undoubtedly showed that the combi-
nation treatment induces significantly more DNA-fragmentation than vehicle or single treatments (Fig. 2A and 
Supplementary Figure 2). Second, to more specifically measure apoptosis, we conducted Annexin V/propidium 
iodide staining. Akin to the DNA-fragmentation, we found the highest proportion of Annexin V positive cells in 
the combination treatment (Fig. 2B). Third, we measured mitochondrial membrane potential after treatment with 
vehicle, ABT263, selinexor and the combination treatment since loss of mitochondrial membrane potential precedes 
release of cytochrome-c from mitochondria, that in turn activates the apoptosome with cleavage of caspase-9. As 
anticipated, the combination treatment more potently disrupted mitochondrial membrane potential than vehicle 
or single treatment in all three cell lines (Fig. 2C). Finally, we determined activation of initiator- (caspase-9) and 
effector-caspases (caspase-3) in the context of our various treatments by performing western blot analysis of the total 
as well as the cleaved forms of caspases. It is well accepted that cleavage of caspases correlates with their activation. 
We found that the combination treatment led to a profound cleavage of caspases with reduction/disappearance of 
the total (inactive) forms (Fig. 3A). Akin to caspases, the down-stream substrate of caspases PARP was cleaved as 
well, providing further evidence for the activation of the caspase cascade (Fig. 3A). It should be noted that subop-
timal dosages of ABT263 were used and therefore single treatment with ABT263 does not elicit caspase cleavage.
Activation of caspases on its own may not have functional implications. To this purpose, we utilized the 
pan-caspase inhibitor, zVAD-fmk. We found that zVAD-fmk partially rescued from apoptosis induced by the 
combination treatment, indicating at least a partial implication of caspases in the death (Fig. 3B,C). Collectively, 
these findings suggest that the combination treatment elicits its anti-glioma effects in part through cell death with 
features of apoptosis.
XPO1 inhibition modulates the levels of anti-apoptotic Bcl-2 family members. Key regulators 
for intrinsic apoptosis are the pro- and anti-apoptotic Bcl-2 family molecule and it is well accepted that Mcl-1 
mediates resistance towards BH3-mimetics that target Bcl-2 and Bcl-xL, but not Mcl-1. For this reason, we ana-
lyzed the expression of Bcl-2 family members upon treatment with selinexor in three cell lines (Fig. 4A). While 
Bcl-xL was unchanged, selinexor suppressed Mcl-1 protein levels. Bcl-2 was down-regulated in LN229 and U87, 
respectively, but not in T98G. We also evaluated the expression of pro-apoptotic Noxa, an intrinsic antagonist of 
Mcl-1. While in LN229 we noted a decrease in Noxa levels, we found an increase in T98G and U87 cells upon 
selinexor administration (Fig. 4A). The suppression of Noxa in LN229 is likely a result of Mcl-1 suppression since 
Mcl-1 and Noxa interact with each other and Mcl-1 suppression was the most strongest in LN229 cells upon 
selinexor treatment (Fig. 4A). However, the ratio of Noxa and Mcl-1 is shifted towards a pro-apoptotic state.
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Given the known impact of ABT263 on the levels of Bcl-2 family members, we evaluated the expression of Bcl-
2, Bcl-xL and Mcl-1 upon ABT263, Selinexor and Selinexor +ABT263 treatment. While ABT263 up-regulated 
Mcl-1 protein levels, this increase was attenuated in the presence of selinexor, thus mediating a pro-apoptotic state 
(Fig. 4A). To better appreciate the course of the events, we conducted a time-course analysis for Mcl-1 levels upon 
Figure 1. The combination treatment of BH3-mimetics and selinexor synergistically reduce cellular proliferation 
of glioblastoma cells. (A) The indicated glioblastoma cell lines, LN229, T98G and GBM12 (patient-derived 
xenograft) cells, were treated with increasing concentrations of selinexor in the presence or absence of the BH3-
mimetic, ABT263, at 1 μM. After 72 h, cell viability assays were performed and IC50 values were calculated, using 
non-linear regression. Shown are means and SD. (B) LN229, T98G or GBM12 (patient-derived xenograft) cells 
were treated with a range of concentrations of ABT263, selinexor or the combination. 72 h after treatment, cell 
viability assays were performed and synergism analysis was performed. Shown are the isobolograms for the three 
different cell lines. Points below the border line are considered synergistic, whereas points above are antagonistic. 
Points on the line are additive. (C) LN229, T98G and GBM12 (patient-derived xenograft) cells were treated as in 
B. Shown is the combination index (CI) vs. the fractional response rate (Fa). CI values smaller than 1.0 indicate 
a synergistic interaction. (D) LN229 GBM cells were treated with selective BH3-mimetics, ABT199 (Bcl-2 
inhibitor), WEHI-539 (Bcl-xL inhibitor) or A1210477 (Mcl-1 inhibitor) in the presence or absence of selinexor. 
Contr: Control, Shown are means and SD of total luminescence values. *p < 0.05; **/***/****p < 0.01.
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selinexor or ABT263+ selinexor treatment. Our findings show that Mcl-1 protein levels are suppressed as early as 
6 h by selinexor, demonstrating that Mcl-1 decrease is an early event (Fig. 4B).
Moreover, we determined Mcl-1 mRNA levels upon ABT263, selinexor and the combination treatment. 
We found that selinexor slightly reduced Mcl-1 mRNA levels, but this suppression was less as compared to the 
reduction on protein level (Fig. 4C). Moreover, while the combination treatment of ABT263+ Selinexor did not 
reduce the Mcl-1 mRNA levels, it strongly suppressed protein levels (Fig. 4B,C). Therefore, it is highly likely that 
selinexor affects Mcl-1 levels at the transcriptional and posttranslational level.
Down-regulation of Mcl-1 is a central mechanism by which selinexor sensitizes glioblastoma 
cells for ABT263 mediated cell death with features of apoptosis. Since Mcl-1 levels were predomi-
nantly affected by selinexor treatment, we proceeded to test the hypothesis that Mcl-1 is likely a functional medi-
ator in cell death mediated by the combination treatment. To this purpose, we used Mcl-1 specific siRNA and 
silenced the expression of Mcl-1 in LN229 GBM cells (Fig. 5C). Silencing was validated by western blotting. 
Figure 2. The combination treatment of ABT263 and selinexor shows features of apoptotic cell death. (A) 
LN229, T98G and U87 GBM cells were treated with ABT263, selinexor or the combination. After 72 h, cells 
were harvested, fixed, stained with propidium iodide and analyzed by flow cytometric analysis for DNA – 
fragmentation. Shown are representative flow cytometry plots. (B) The same set of cell lines as in A were treated 
with the indicated drugs and the same conditions (except for the incubation time, which was 24 h). Thereafter, 
cells were stained with Annexin V/Propidium iodide and analyzed by multi-parametric flow cytometry. Shown 
are representative plots. (C) The same set of cell lines as in A were treated with the indicated drugs and the 
same conditions (except for the incubation time, which was 24 h). Thereafter, cells were stained with TMRE and 
analyzed by flow cytometry. Shown are representative flow plots.
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After transfection, LN229 transfected with non-targeting or Mcl-1 specific siRNA were subjected to treatment 
with vehicle, ABT263, Selinexor and ABT263+ Selinexor. While non-targeting siRNA had minimal effects on 
DNA-fragmentation, Mcl-1 silencing led to a mild to moderate increase in DNA-fragmentation, suggesting that 
Mcl-1 is important for survival of LN229 cells (Fig. 5A,B). We found that Mcl-1 silencing drastically sensitized for 
ABT263 mediated cell death, whereas selinexor mediated DNA-fragmentation was not enhanced as compared 
to the Mcl-1 siRNA alone (Fig. 5A,B). Finally, we evaluated the effect of Mcl-1 silencing on the combination 
treatment of ABT263+ selinexor. Mcl-1 silencing further enhanced the effects of the combination treatment on 
cell death (Fig. 5A,B). A second experiment was performed in T98G cells, which mirrors the findings obtained 
in LN229 cells (Supplementary Figure 3A–C). Taken together, these observations strongly suggest that Mcl-1 is a 
key mediator of cell death mediated by the combination treatment.
The combination treatment of ABT263 and Selinexor reduces tumor growth in a murine patient- 
derived xenograft model of glioblastoma. The assessment as to whether or not a proposed preclinical 
drug combination is efficacious in animal models is of highest importance since it allows to determine in vivo 
efficacy while at the same time it provides information about potential toxicities. The emergence of patient-derived 
xenograft has greatly assisted to ensure that in vivo models are biologically closest to patients‘ tumors. Therefore, we 
Figure 3. The combination treatment of ABT263 and selinexor elicits apoptosis in a partial caspase-dependent 
manner. (A) LN229, T98G and U87 GBM cells were treated with ABT263, selinexor or the combination. 
Thereafter, whole-cell protein lysates were harvested and analyzed by conventional western blotting for the 
expression of PARP, caspase-9 (CP9), cleaved caspase-3 (cCP3) and Actin. TF: total form, CF: cleaved form. 
(B) T98G cells were treated with vehicle or the combination treatment of ABT263+ selinexor in the presence 
or absence of pan-caspase inhibitor, zVAD-fmk. Thereafter, cells were fixed, stained with propidium iodide 
and analyzed by flow cytometry. Shown are representative flow plots. (C) The experiment in B was quantified 
and statistical analysis was performed. (C) Control, AS: ABT263+ Selinexor, Z: zVAD-fmk, ZAS: ZVAD-
fmk + ABT263+ Selinexor. Shown are means and SD. *p < 0.05; **/***/****p < 0.01.
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determined the in vivo efficacy of ABT263, Selinexor and the combination in a patient-derived xenograft model of 
glioblastoma. We utilized the GBM12 models in a manner similar as described in previous studies. In this regard, 
the subcutaneous model system provides a relevant and resource-efficient approach to assess treatment efficacy 
and toxicity in vivo. After the establishment of PDX tumors, four treatment groups were established: A, Vehicle, 
B, ABT263, C, Selinexor, D, ABT263+ Selinexor. Treatment was administered until the defined endpoint of the 
study was reached. While both selinexor and ABT263 showed some suppression of tumor growth, the combina-
tion treatment was most potent, confirming our in vitro findings (Fig. 6A–E). Despite this significant efficacy, it is 
noteworthy that there was no toxicity associated with the combination treatment as determined by weight meas-
urement and general health assessment of the animals during and after the treatments (Fig. 6B). We further asked 
the questions by which manner ABT263+ Selinexor exerted these potent growth inhibitory effects. Based on the 
in vitro findings, it was highly likely that this involves induction of cell death. However, given the quite different 
settings we validated this hypothesis by staining tumor tissue with standard HE staining from each individual 
treatment group. As anticipated, the control tumors displayed a high cell density with numerous mitotic figures 
with few areas of necrosis (Fig. 6E). In contrast, the combination treatment demonstrated vast areas of tumor cell 
necrosis accompanied by TUNEL positive cells, supporting the notion that the combination treatment exerted 
its biological effects predominantly through cell death induction (Fig. 6E,F). This notion is of significance since a 
tumor regression may only be accomplished by treatments that have the ability to induce cell death.
Figure 4. Inhibition of XPO1 by selinexor regulates the expression of anti- and pro-apoptotic Bcl-2 family 
member proteins. (A) LN229, T98G and U87 GBM cells were treated with ABT263, selinexor or the 
combination. Alternatively, cells were treated with increasing concentrations of selinexor for 24 h. Thereafter, 
whole cell protein lysates were collected and analyzed by conventional western blotting for the expression of 
Mcl-1, Bcl-2, Bcl-xL, Noxa and Actin. All concentrations are in μM. (B) LN229 GBM cells were treated with 
selinexor or the combination treatment of ABT263+ selinexor for the indicated time points (time course 
experiment). Thereafter, whole cell protein lysates were prepared and analyzed for the expression of Mcl-1. Hrs: 
hours. (C) LN229 GBM cells were treated with vehicle, ABT263, selinexor or the combination treatment. After 
6 h, RNA was harvested, reverse transcribed and subjected to real-time PCR analysis for Mcl-1.
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Discussion
The quest for more durable treatment approaches remains a priority in cancer research given the fact that many 
malignancies still harbor a dismal prognosis13. Belonging to this group are malignant glial tumors, such as glio-
blastoma14. Recent changes in the classification scheme of these tumors have been made, which refers in particu-
lar to a discovery of mutations in the IDH1 gene14. While a huge portion of novel findings with regards to the 
molecular classification has been made, therapeutic advances lack behind. In light of the fact that an abundance of 
small molecule inhibitors that specifically target newly discovered alterations it is of high relevance to determine 
potential therapeutic treatment regimens, involving these compounds or combination of them15–18. As stated ear-
lier, drug combinations are likely to be the key for the identification of novel treatments since virtually all tumors 
depend on multiple signaling cascades18–21. In this work, we have followed this strategic pattern and describe 
a novel synthetic lethal interaction between XPO1 and Bcl-2/Bcl-xL inhibition. To accomplish this, we took 
advantage of the XPO1 inhibitor, selinexor, and the Bcl-2/Bcl-xL inhibitor, ABT2631–3. The combination of these 
compounds potently induced cell death with features of apoptosis in several glioblastoma culture model systems 
in a highly synergistic manner. More relevantly, we tested the combination treatment in a patient-derived xeno-
graft model of human GBM and found that tumors treated with ABT263 and Selinexor were significantly smaller 
than tumors treated with single compounds or vehicle. It is also notable that we did not detect any form of toxicity 
throughout that treatment. To the best of our knowledge, we are the first to describe such observations in the 
context of malignant glial brain tumors. Given the fact that selinexor penetrates the blood-brain barrier and has 
Figure 5. Mcl-1 is the key regulator in the combination treatment, involving ABT263 and Selinexor. (A) 
LN229 GBM cells were transfected with non-targeting or Mcl1-specific siRNA for 72 h. Non-targeting and 
Mcl-1 specific siRNA transfected cells were subsequently exposed to vehicle, ABT263 (ABT), selinexor (Sel) 
or the combination treatment of ABT263 and selinexor (ABT + Sel). Thereafter, cells were fixed, labeled with 
propidium iodide and analyzed by flow cytometry. Shown are representative plots. (C) Control; SI: Mcl-1 
specific siRNA.; NT: non-targeting siRNA. (B) Shown are the quantifications obtained from experiment 
performed in A. Shown are means and SD. (C) LN229 GBM cells were transfected as in A. Whole cell protein 
lysates were collected and analyzed for the expression of Mcl-1 and Bcl-xL by standard western blotting (C: 
Control, non-targeting siRNA; SI: siRNA Mcl-1).
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reached phase-II clinical testing, such a combination therapy is a potential viable option for patients. However, 
it should be noted that the model systems used here does not have a blood-brain barrier (due to subcutaneous 
tumor localization). In addition, a further limitation is that the micro-environment in an orthotopic location is 
different from the one in the cutis. While our observations are restricted to glioblastoma, it is noteworthy that this 
approach might have a role in other solid tumors as well. It is well accepted that the anti-apoptotic Bcl-2 family 
Figure 6. The combination treatment of ABT263 and selinexor reduces tumor growth stronger than vehicle or 
single treatments in a patient-derived xenograft model of human GBM. (A) Patient-derived xenograft model 
(GBM12) was implanted subcutaneously in nude mice. Once tumors became palpable and were about to 
enter an exponential growth rate, four treatment groups were randomly assigned: A, Vehicle (Ctrl), ABT263, 
selinexor or ABT263 + selinexor (A + S). Two treatments were given, consisting of vehicle, 75 mg/kg ABT263, 
10 mg/kg selinexor or the combination. Tumor growth was measured and is plotted as volume over time (days). 
Shown are means and SD. (B) for the same experiments described in A weight measurements were taken for 
the individual groups. (C) On the day of conclusion of the experiment described in A, statistical analysis was 
performed. Shown are means and SD. (D) Representative gross images of the individual groups are shown 
after conclusion of the experiment. A + S: ABT263 + selinexor. (E) Tumors from the individual groups were 
fixed, embedded in paraffin and paraffin section were stained with standard hematoxylin and eosin staining 
(H&E). Shown are representative images from the individual treatment groups. F, Tumors from the indicated 
groups were stained with TUNEL. Representative images are shown and arrows highlight TUNEL positive cells. 
*p < 0.05; **/***/****p < 0.01.
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members play a significant role in other major solid malignancies, such as colon, lung and breast cancer, which 
are far more frequent than malignant glial brain tumors22.
Mechanistically, we demonstrated that cell death with features of apoptosis is activated by the combination 
treatment and that this is likely be mediated through the impact of selinexor on Mcl-1 protein levels. We cannot 
exclude the possibility that other forms of cell death, such as non-caspase dependent mediated cell death, are 
contributing to our assessed drug-synergy. With regards to Mcl-1, we validated its involvement by siRNA exper-
iments. Mcl-1 is a bona-fide mediator of resistance towards BH3-mimetics that target either Bcl-2, Bcl-xL or the 
combination of the two. More recently, selective Mcl-1 inhibitors were designed and in these molecules are poten-
tially amenable to clinical translation. Akin to the former BH-3 mimetics, ABT737 and ABT263, Mcl-1 inhibi-
tors might be particularly well-suited for drug combination therapies7,15. In the context of glioblastoma, public 
databases suggest that Mcl-1 is up-regulated in these tumors as compared to normal brain tissue. The pitfall of 
these Mcl-1 specific BH3-mimetics is their relatively large molecular size, which may dampen the penetrance of 
this compound class through the blood brain barrier. It is also for this reason that other modalities or compounds 
are necessary to interfere with Mcl-1 levels in high grade gliomas. Selinexor may be such a molecule since it 
penetrates the blood-brain-barrier and lowers Mcl-1 levels. Other strategies to lower Mcl-1 levels are to lower its 
transcription, synthesis or in particular to enhance its proteasomal degradation19,23–26. Concerning proteasomal 
degradation, it is well known that Mcl-1 is an unstable protein that through phosphorylation/dephosphorylation 
is subjected to proteasomal degradation19,23–26.
Collectively, we have provided a foundation to further develop a drug combination that targets Bcl-2/Bcl-xL 
and XPO1.
Materials and Methods
Reagents. Selinexor, ABT263, ABT199, WEHI-539 and A1210477 were purchased from Sellekchem.
Cell cultures and growth conditions. U87MG, LN229 and T98G human glioblastoma cell lines were 
obtained from the American Type Culture Collection (Manassas, VA). The respective cell line depository authen-
ticated the cells. The NCH644 stem-like GBM cells (non-adherent) were purchased from (CLS, Heidelberg, 
Germany) and cultured in MG-43 medium (CLS, Heidelberg, Germany) for maintenance and experiments. The 
GBM12 cells were extracted from the tumor and cultured as indicated in detail in the following reference27.
Cell viability assays. Viability assays were performed as previously described28–30. 4000 cells were seeded 
in 96-well plates prior treatments with the indicated BH3-mimetics (ABT263, WEHI-539, A1210477, ABT199) 
or the XPO1 inhibitor, selinexor. Briefly, anti-proliferative effects were determined by using the CellTiter-Glo 
(Promega, Madison, WI) luminescent cell viability assay in 96-well plates 72 h after treatment according to the 
protocol as described by the manufacturer. We utilized the CompuSyn software (ComboSyn, Inc., Paramus, NJ) 
to assess drug synergism, which involves the computation of the combination index (CI). A CI <1 was defined as 
synergistic, a CI = 1 as additive and a CI >1 as antagonistic.
Measurement of apoptosis and mitochondrial membrane potential. For Annexin V/propidium 
iodide staining the Annexin V Apoptosis Detection Kit (BD Pharmingen) was used as previously described31,32. 
TMRE staining was performed according to the manufacturer’s instructions (Mitochondrial Membrane Potential 
kit, Cell Signaling Technology, Danvers, MA). The data were analyzed with the FlowJo software (version 8.7.1; 
Tree Star, Ashland, OR).
Transfections of siRNAs. Transfections with non-targeting or Mcl-1 specific siRNAs were performed with 
Oligofectamine® 2000 (Invitrogen, Carlsbad, CA) or Oligofectamine as described in31,32.
Western blot analysis. Specific protein expression in cell lines was determined by Western blot analysis as 
described before. Uncropped gel images are provided in the supplementary section.
Real-time PCR analysis. Real-time PCR analysis was performed for Mcl-1 with primers and methodology 
as earlier described33,34.
Subcutaneous patient-derived xenograft model. The GBM12 PDX model was used for in vivo effi-
cacy assessment. This model was established and described by Dr. Jann Sarkaria35. Selinexor (10 mg/kg) and 
ABT263 (75 mg/kg) were dissolved in 10% DMSO, 32% Cremophor EL (SIGMA, St. Louis, MO), 8% Ethanol 
(Pharmco-Aaper, Brookfield,CT) and 50% PBS. Treatments were administered on day 6 and 10 (after cell implan-
tation) at the dosage described above (intraperitoneal injections).
Statistical analysis. Statistical significance was assessed by Student’s t-test using Prism version 7.00 
(GraphPad, La Jolla, CA). A p ≤ 0.05 was considered statistically significant. Drug synergy analysis was per-
formed to detect synergistic, additive or antagonistic effects as previously described36,37.
Ethical approval. All procedures were in accordance with Animal Welfare Regulations and approved by the 
Institutional Animal Care and Use Committee at the Columbia University Medical Center.
Data Availability Statement
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information files).
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